The targeted platform drug Cabometyx is labeled for liver cancer treatment

today the FDA approved Exelixis' cMET/VEGFR inhibitor Cabomeyx (commonly named cabozantinib) tablets for treatment in HCC patients using solafinib. The approval was based on the results of a phase III clinical trial called CELESTIAL, which recruited 707 HCC patients who had used sorabinib and resulted in cabozantinib being 2.2 months longer than a placebo OS (10.2 to 8.0 months) and a 24 percent lower risk of death. The PFS difference was 3.3 months (5.2 to 1.9 months) and the trial was terminated early due to efficacy. In terms of safety, 16% of patients in the drug group and 3% of patients in the placebo group were withdrawn due to adverse reactions, of which 6 died of adverse reactions in the drug group and one person in the placebo group died of liver failure. Exelixis shares edged up 5 percent today.Cabozantinib capsules were first listed in 2012 under the trade name Cometriq for a rare form of thyroid cancer, but it's a micro-adaptation that only has a few hundred people. In 2014, a phase III clinical failure of prostate cancer, the same day 70% of layoffs, broken bones. The tablet was later awarded the RCC second-line and first-line label in 2016 and 2017 under the commodity name Cabometyx, especially in the first-tier RCC, becoming the first kidney cancer drug to beat Soltan in 10 years. Today's approval is the fourth label for Cabozantinib, a drug that combines with Roche PD-L1 antibody Tecentriq in phase III clinical trials on the HCC front line and may move forward further. This product is in the process of several other solid tumor clinical trials, like a platform drug.many of the most important pathotic drugs have a number of adaptive disorders, such as TNF, PD-1 antibodies have more than a dozen allergens, this drug is often called platform drugs. The platform has the meaning of a pillar, so generally refers to the market larger drugs. Vitrakvi, a recently marketed NTRK inhibitor, is available on all NTRK fusion tumors, but is difficult to call a platform drug because of its small fusion ratio. Cabozantinib is also different from pan-tissue targeted therapies because there are no biomarker requirements for adaptation. The product, which sells for less than $1 billion a year, is definitely the backbone for Exelixis. It is less common for kinase inhibitors to obtain multiple adaptations, so Cabozantinib can be counted as a targeted platform drug relatively speaking, and of course, because there are no adaptations, it can only be counted as a civilian platform drug at present.Cabozantinib, though described as a MET/VEGFR2 inhibitor, is very poorly selective, with many innocents estimated to have been mistakenly injured at therapeutic doses, working in a manner more similar to traditional cytotoxic anticancer drugs. Although both MET and VEGFR are confirmed targets, Cabozantinib's pharmacology may be more complex than inhibiting both proteins, and its essence is closer to a glomerical drug with ambiguousity. The complexity of the process certainly increases the risk of development, as it is difficult to predict which tumor benefits outweigh the risk, and it is more difficult for each adaptive segment of the population. So Exelixis deserves credit for its courage and clinical development skills, as it has been able to achieve great results after its collaborator, Shi Guibao, left home.advantage of this drug is that if your adventure is successful, it's hard for other manufacturers to find me-too drugs to compete with you, and of course it's not easy for you to develop follow-up drugs yourself. Instead of continuing to invest in a product that is about to face generic erosion, manufacturers typically develop a generic follow-up drug to make new adaptations when drug patents are about to expire. A well-known example is King Pharmaceutical's ACE inhibitor Altace, which was labeled heart failure after the expiration of the old ACE inhibitor patent and sold at a high price for many years. Although both Cometriq and Cabometyx have black-box warnings (which can cause severe or even fatal bleeding, and some patients have colon perforations) and few patents remain on the compound, Exelixis continues to invest heavily in developing the product because of its pharmacological difficulties. (Bio Valley)